TCR² Therapeutics to Participate in Two Upcoming Conferences in March

Rhea-AI Summary

On March 3, 2021, TCR² Therapeutics (Nasdaq: TCRR) announced upcoming presentations at two virtual conferences in March. Ian Somaiya, CFO, will present at the H.C. Wainwright Global Life Sciences Conference on March 9, 2021, at 7:00 am ET. Somaiya will also join Robert Hofmeister, CSO, for a fireside chat at the 33rd Annual Roth Conference on March 17, 2021, at 11:00 am ET. Live webcasts will be available on the company's Investors page, with archived replays for at least 30 days.

CAMBRIDGE, Mass., March 03, 2021 (GLOBE NEWSWIRE) -- TCR² Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage immunotherapy company with a pipeline of novel T cell therapies for patients suffering from cancer, today announced that management will present an update on Company progress at two upcoming conferences in March using a virtual platform.

• Ian Somaiya, Chief Financial Officer of TCR² Therapeutics, will present corporate presentation at the H.C. Wainwright Global Life Sciences Conference on March 9, 2021 at 7:00am ET
• Ian Somaiya, Chief Financial Officer of TCR² Therapeutics, and Robert Hofmeister, Ph.D., Chief Scientific Officer of TCR² Therapeutics, will participate in a fireside chat at the 33rd Annual Roth Conference on March 17, 2021 at 11:00am ET

A live webcast of the presentation will be available on the Investors page of the Company’s website at www.investors.tcr2.com. An archived replay will be available for at least 30 days following the presentation.

About TCR² Therapeutics

TCR² Therapeutics Inc. is a clinical-stage immunotherapy company developing a pipeline of novel T cell therapies for patients suffering from solid tumors or hematological malignancies. TCR²’s proprietary T cell receptor (TCR) Fusion Construct T cells (TRuC^®-T cells) specifically recognize and kill cancer cells by harnessing signaling from the entire TCR, independent of human leukocyte antigens (HLA). In preclinical studies, TRuC-T cells have demonstrated superior anti-tumor activity compared to chimeric antigen receptor T cells (CAR-T cells), while secreting lower levels of cytokine release. The Company’s lead TRuC-T cell product candidate targeting solid tumors, gavo-cel, is currently being studied in a Phase 1/2 clinical trial to treat patients with mesothelin-positive non-small cell lung cancer (NSCLC), ovarian cancer, malignant pleural/peritoneal mesothelioma, and cholangiocarcinoma. The Company’s lead TRuC-T cell product candidate targeting hematological malignancies, TC-110, is currently being studied in a Phase 1/2 clinical trial to treat patients with CD19-positive adult acute lymphoblastic leukemia (aALL) and with aggressive or indolent non-Hodgkin lymphoma (NHL). For more information about TCR², please visit www.tcr2.com.

Investor and Media Contact:

Carl Mauch
Director, Investor Relations and Corporate Communications
TCR² Therapeutics Inc.
(617) 949-5667
carl.mauch@tcr2.com

FAQ

What conferences will TCR² Therapeutics attend in March 2021?

TCR² Therapeutics will present at the H.C. Wainwright Global Life Sciences Conference on March 9, 2021, and participate in a fireside chat at the 33rd Annual Roth Conference on March 17, 2021.

Who will present on behalf of TCR² Therapeutics at the upcoming conferences?

Ian Somaiya, CFO, will present at the H.C. Wainwright Global Life Sciences Conference, while he and Robert Hofmeister, CSO, will participate in a fireside chat at the Roth Conference.

Where can I watch the TCR² Therapeutics conference presentations?

Live webcasts of the presentations will be available on the Investors page of TCR² Therapeutics' website.

When will the presentations from TCR² Therapeutics be available for replay?

Archived replays of the presentations will be available for at least 30 days following the events.

What is the stock symbol for TCR² Therapeutics?

The stock symbol for TCR² Therapeutics is TCRR.